<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716377</url>
  </required_header>
  <id_info>
    <org_study_id>104106</org_study_id>
    <nct_id>NCT01716377</nct_id>
  </id_info>
  <brief_title>Healing With Venlafaxine After Injury (HELP)</brief_title>
  <acronym>HELP</acronym>
  <official_title>Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayday Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The purpose of this study is to demonstrate the potential efficacy of venlafaxine&#xD;
      administration in reducing acute and chronic musculoskeletal pain in individuals presenting&#xD;
      to the ED for evaluation after motor vehicle collision.&#xD;
&#xD;
      Participants: Participants will consist of 60 patients between the ages of 18-50 who present&#xD;
      to the ED within 12 hours post-motor vehicle collision. Patients who report a neck pain score&#xD;
      &gt; 6 will be screened for further eligibility.&#xD;
&#xD;
      Procedures (methods): Using a placebo-controlled, randomized, double-blind trial design, 60&#xD;
      high risk patients will be randomized to venlafaxine vs. placebo in the ED. The ability of&#xD;
      venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed&#xD;
      during serial short-term telephone follow-ups as well as more in-depth follow-ups at 6 weeks,&#xD;
      4 months, and 6 months post-MVC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results from both animal and human studies suggest that treatment with the&#xD;
      serotonin-norepinephrine reuptake inhibitor (SNRIs) venlafaxine may reduce post-MVC pain. In&#xD;
      addition, venlafaxine has been shown to be beneficial in reducing posttraumatic stress&#xD;
      disorder (PTSD) symptoms, and in some patients PTSD symptoms may contribute to reinforcing&#xD;
      pain persistence after trauma.&#xD;
&#xD;
      This phase IIB pilot trial will screen patients presenting to the ED after MVC for the&#xD;
      presence of severe axial pain (&gt;4 on a 0-10 numeric rating scale). Sixty of these &quot;high risk&quot;&#xD;
      patients will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to&#xD;
      decrease acute and persistent musculoskeletal axial pain will be assessed.&#xD;
&#xD;
      Results will be used to design a large-scale RCT assessing the efficacy of venlafaxine&#xD;
      intervention in decreasing acute and persistent musculoskeletal pain in high-risk patients&#xD;
      presenting to the ED after minor MVC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average neck pain</measure>
    <time_frame>0-31 Days</time_frame>
    <description>The primary outcome variable is average neck pain (0 - 10 numeric rating pain score recorded from patient) after study drug initiation through Day 31.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic neck pain</measure>
    <time_frame>Study day 38 through 6 months</time_frame>
    <description>The secondary outcome variable is average neck pain (0 - 10 numeric rating pain score recorded from patient) between study day 38 through 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Neck Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venlafaxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Venlafaxine</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18 and 59&#xD;
&#xD;
          -  Presents to ED within 24 hours of MVC&#xD;
&#xD;
          -  ED axial pain score greater than or equal to 4 (0-10 NRS)&#xD;
&#xD;
          -  Clinically sober&#xD;
&#xD;
          -  Willing to provide a blood sample&#xD;
&#xD;
          -  Has a telephone&#xD;
&#xD;
          -  Has regular access to Internet and an email address&#xD;
&#xD;
          -  Able to speak and read English&#xD;
&#xD;
          -  Permanent US citizen or has a green card&#xD;
&#xD;
          -  Blood pressure reading(s) in ED that, when considered in the context of patient past&#xD;
             and current history, in the investigator's judgment does not exceed acceptable level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Axial pain score greater than 0 in the past month (0-10 NRS)&#xD;
&#xD;
          -  Clinically unstable&#xD;
&#xD;
          -  Fracture (other than fracture of the phalanges)&#xD;
&#xD;
          -  Substantial soft tissue injury&#xD;
&#xD;
          -  Hepatic failure (acute or chronic)&#xD;
&#xD;
          -  Renal failure (acute or chronic)&#xD;
&#xD;
          -  Coronary artery disease, including previous MI, Angina, PCTA, etc.&#xD;
&#xD;
          -  History of glaucoma&#xD;
&#xD;
          -  Previous congestive heart failure&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of mania or psychotic disorder&#xD;
&#xD;
          -  History of suicidal ideation&#xD;
&#xD;
          -  Prisoner&#xD;
&#xD;
          -  History and behavior indicates, in the investigator's judgment, that the participant&#xD;
             would likely be noncompliant with the study&#xD;
&#xD;
          -  Any other condition that, in the investigator's judgment, would indicate that the&#xD;
             patient in unsuitable for the study (e.g. might interfere with the study, confound&#xD;
             interpretation, or endanger patient)&#xD;
&#xD;
          -  Currently taking a monoamine oxidase inhibitor&#xD;
&#xD;
          -  Currently taking medication with substantial interaction with venlafaxine, or which&#xD;
             could confound interpretation of study results&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  If female, either not postmenopausal (having menses within past year), or, if&#xD;
             childbearing potential, positive pregnancy test prior to randomization and not using a&#xD;
             medically acceptable form of contraception&#xD;
&#xD;
          -  Exceeds acceptable chronic daily opioid use prior to MVC&#xD;
&#xD;
          -  Previously on venlafaxine&#xD;
&#xD;
          -  Previous allergic reaction to venlafaxine&#xD;
&#xD;
          -  Antidepressant use within 2 weeks of study start (4 week if Prozac)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel A McLean, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirsten Rindal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Fermann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>October 25, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rhode Island Hospital</investigator_affiliation>
    <investigator_full_name>Francesca Beaudoin</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Neck Pain</keyword>
  <keyword>Musculoskeletal pain</keyword>
  <keyword>Venlafaxine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neck Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

